Table 5.
Tumor stage demographics of patients based on the chemotherapeutic treatment decisions of the best-performing model (n=134).
| Demographics | Chemotherapy | No chemotherapy, no induction chemotherapy, radiotherapy alone (%; 95% CI) | ||||||
|
|
Induction chemotherapy | No induction chemotherapy, concurrent chemotherapy (%; 95% CI) |
|
|||||
|
|
Concurrent chemotherapy (%; 95% CI) | Radiotherapy alone (%; 95% CI) |
|
|
||||
| Ta category | ||||||||
|
|
T1 | 23.08 (0-65.38) | 3.85 (0-26.92) | 69.23 (26.92- 96.15) | 0 (0-23.08) | |||
|
|
T2 | 25.40 (6.35-55.56) | 3.17 (0-22.22) | 66.67 (38.06-88.89) | 0 (0-20.63) | |||
|
|
T3 | 32 (8-64.1) | 4 (0-28) | 60 (28-88) | 0 (0-16) | |||
|
|
T4 | 36.84 (5.26-84.21) | 5.26 (0-31.58) | 52.63 (10.53-94.74) | 0 (0-15.79) | |||
|
|
Txb | 0 (0-100) | 0 (0-100) | 100 (0-100) | 0 (0-100) | |||
| Nc category | ||||||||
|
|
N0d | 20 (0-100) | 0 (0-40) | 60 (0-100) | 0 (0-40) | |||
|
|
N1 | 17.39 (0-73.91) | 0 (0-30.43) | 73.91 (17.39-95.65) | 0 (0-21.74) | |||
|
|
N2 | 29.41 (9.80-56.89) | 3.92 (0-22.55) | 62.75 (36.27-81.37) | 0 (0-17.65) | |||
|
|
N3 | 25 (0-100) | 0 (0-50) | 50 (0-100) | 0 (0-25) | |||
| N category (8th editione) | ||||||||
|
|
N0 | 16.67 (0-100) | 0 (0-33.33) | 66.67 (0-100) | 0 (0-33.33) | |||
|
|
N1 | 22.06 (2.94-60.29) | 2.94 (0-26.47) | 70.59 (30.88-92.65) | 0 (0-22.06) | |||
|
|
N2 | 33.93 (8.93-69.64) | 3.57 (0-26.79) | 58.93 (25-83.93) | 0 (0-14.29) | |||
|
|
N3 | 25 (0-100) | 0 (0-50) | 50 (0-100) | 0 (0-25) | |||
aT: primary tumor.
bTx: no information about the primary tumor or it cannot be measured.
cN: lymph nodes.
dN0: nearby lymph nodes do not contain cancer.
eAmerican Joint Committee on Cancer’s Cancer Staging Manual, 8th edition.